SHERIDAN, WYOMING – May 8, 2025 – Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a recognized leader in life science research and clinical diagnostics products, is set to announce its first-quarter financial results for 2025 on Thursday, May 1, 2025. The company will release its earnings after market close, followed by a detailed conference call to discuss the results.
Key Highlights of the Upcoming Report
Bio-Rad, headquartered in Hercules, California, is poised to share insights into its financial performance, reflecting ongoing growth and market leadership in the life sciences sector. The company’s diverse product portfolio spans across research and clinical diagnostics, with an emphasis on innovation and customer success.
Following the release of the financial results, Bio-Rad's management will host a conference call at 2:30 PM Pacific Time (5:30 PM Eastern Time) to discuss the outcomes in detail. This call offers analysts, investors, and stakeholders a comprehensive understanding of the company’s financial health and market position.
Conference Call Participation Details
Interested parties can access the conference call through the following methods:
- Domestic participants: Dial (800) 715-9871
- International participants: Dial (646) 307-1963
- Access code: 9562470
For those unable to join the live call, Bio-Rad will also provide a webcast of the conference, available under the “Investor Relations” section of the company’s website at investors.bio-rad.com. The webcast replay will be accessible for up to one year.
About Bio-Rad Laboratories, Inc.
With nearly 7,700 employees and an annual revenue of $2.6 billion in 2024, Bio-Rad Laboratories continues to lead the way in the development, manufacturing, and marketing of innovative products across the life science and clinical diagnostics sectors. Its customers include top-tier universities, research institutions, hospitals, biopharmaceutical companies, and laboratories focusing on clinical, food safety, and environmental quality testing.
The company’s broad range of solutions is critical to advancing scientific discovery and improving patient care, demonstrating Bio-Rad’s deep commitment to driving excellence in the medical and research fields.
As Bio-Rad remains at the forefront of scientific innovation, the company’s upcoming first-quarter financial results will offer key insights into its strategic direction and continued market impact.
For more information, visit Bio-Rad’s website.